Purpose
Taste alteration (TA) is a common and distressing side effect of chemotherapy, particularly in older adults. It often leads to appetite loss and malnutrition. In this study, we (1) estimated the prevalence of chemotherapy-induced TA; (2) investigated its correlations with xerostomia, oral health, and health-related quality of life (HRQoL); and (3) explored its key predictors in older patients with cancer.
Methods
This cross-sectional study included 120 older patients with cancer (age: ≥65 years) receiving chemotherapy in a regional hospital in Taiwan. Relevant data were collected using validated instruments, such as the Chemotherapy-Induced Taste Alteration Scale, Xerostomia Questionnaire, Oral Health Assessment Tool, and Taiwan Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Stepwise multiple regression was performed to identify significant predictors of TA.
Results
The prevalence of TA in the study cohort was 93 %. Patients with TA had significantly worse xerostomia scores (mean score: 21.31 ± 15.00) and oral health scores (mean score: 6.15 ± 2.60) than did those without TA (p < .05). TA was significantly correlated with HRQoL, xerostomia, and oral health. Xerostomia was the strongest independent predictor of TA (β = .51; p < .001), followed by HRQoL and previous chemotherapy, which together explained 32 % of the total variance in TA severity.
Conclusion
Chemotherapy-induced TA is highly prevalent among older patients with cancer, and it markedly reduces their quality of life. Supportive oncology care for this population should integrate interventions addressing xerostomia and oral health.
扫码关注我们
求助内容:
应助结果提醒方式:
